Pharmacokinetics of rufloxacin once daily in patients with lower respiratory tract infections

Infection ◽  
1992 ◽  
Vol 20 (2) ◽  
pp. 89-93 ◽  
Author(s):  
R. Rimoldi ◽  
M. Fioretti ◽  
A. Albrici ◽  
B. P. Imbimbo
Keyword(s):  
Respiratory Tract ◽  
Lower Respiratory Tract ◽  
Respiratory Tract Infections ◽  
Lower Respiratory Tract Infections ◽  
Once Daily ◽  
Tract Infections

scholarly journals Clinical Studies of Oral Quinolone Once Daily in the Treatment of Lower Respiratory Tract Infections.

1993 ◽  
Vol 40 (4) ◽  
pp. 213-218
Author(s):  
TAKAFUMI YANO ◽  
FUMIO TANAKA ◽  
KAZUHIRO OUCHI ◽  
MASAO KAWAHARA ◽  
KAZUMA FUJINO ◽  
...  
Keyword(s):  
Respiratory Tract ◽  
Clinical Studies ◽  
Lower Respiratory Tract ◽  
Respiratory Tract Infections ◽  
Lower Respiratory Tract Infections ◽  
Once Daily ◽  
Tract Infections

An Open, Multicentre, Comparative Study of the Efficacy and Safety of Azithromycin and Co-Amoxiclav in the Treatment of Upper and Lower Respiratory Tract Infections in Children

1997 ◽  
Vol 25 (5) ◽  
pp. 285-295 ◽  
Author(s):  
DVA Lauvau ◽  
L Verbist ◽  
Keyword(s):  
Respiratory Tract ◽  
Lower Respiratory Tract ◽  
Respiratory Tract Infections ◽  
Overall Response Rate ◽  
Response Rate ◽  
Efficacy And Safety ◽  
Lower Respiratory Tract Infections ◽  
Once Daily ◽  
Group A ◽  
Tract Infections

An open prospective, multicentre, comparative, randomized (2:1) study was conducted in 481 children diagnosed as having mild-to-moderate lower respiratory tract infections. The efficacy and safety of azithromycin suspension (10 mg/kg), dosed orally once daily for 3 days, was compared with that of co-amoxiclav (10 mg/kg in a 4:1 ratio), dosed orally three times daily for 5–10 days. The proportion of evaluable patients ( n = 472) showing a cure or improvement was significantly higher in the azithromycin group (96.8%) than in the co-amoxiclav group (91%, P = 0.0199). There were six relapses in both groups, giving an overall response rate of 95% for azithromycin versus 87.1% for co-amoxiclav ( P = 0.0025). Adverse events were reported in 10% of the patients treated with azithromycin, and 11.3% of co-amoxiclav patients. Reported and counted compliance was significantly better in the azithromycin group. A 3-day regimen of azithromycin was as effective and as safe as a 5–10 day regimen of co-amoxiclav in the treatment of respiratory tract infections in children, and compliance was improved.

Once-Daily Tobramycin Therapy in Lower Respiratory Tract Infections

1995 ◽  
Vol 7 (4) ◽  
pp. 371-379 ◽  
Author(s):  
C. Grassi ◽  
F. Ginesu ◽  
E. Pozzi ◽  
R. Rimoldi ◽  
N. Crimi ◽  
...  
Keyword(s):  
Respiratory Tract ◽  
Lower Respiratory Tract ◽  
Respiratory Tract Infections ◽  
Lower Respiratory Tract Infections ◽  
Once Daily ◽  
Tract Infections
Sign in / Sign up

Export Citation Format

Share Document